Journal
CLINICAL AND EXPERIMENTAL MEDICINE
Volume 6, Issue 1, Pages 1-12Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10238-006-0087-6
Keywords
CD20; B-cell lymphoma; Y-90 ibritumomab tiuxetan; I-131 tositumomab
Categories
Ask authors/readers for more resources
CD20 has proven to be an excellent target for the treatment of B-cell lymphoma, first for the chimeric monoclonal antibody rituximab (Rituxan(TM)), and more recently for the radiolabelled antibodies Y-90 ibritumomab tiuxetan (Zevalin(TM)) and I-131 tositumomab (Bexxar(TM)). Radiation therapy effects are due to beta emissions with path lengths of 1-5 mm gamma radiation emitted by 1-131 is the only radiation safety issue for either product. Dose-limiting toxicity for both radiolabelled antibodies is reversible bone marrow suppression. They produce response rates of 70%-90% in low-grade and follicular lymphoma and 40%-50% in transformed low-grade or intermediate-grade lymphomas. Both products produce higher response rates than related unlabelled antibodies, and both are highly active in patients who are relatively resistant to rituximab-based therapy. Median duration of response to a single course of treatment is about 1 year with complete remission rates that last 2 years or longer in about 25% of patients. Clinical trials suggest that anti-CD20 radioimmunotherapy is superior to total body irradiation in patients undergoing stem cell supported therapy for B-cell lymphoma, and that it is a safe and efficacious modality when used as consolidation therapy following chemotherapy. Among cytotoxic treatment options, current evidence suggests that one course of anti-CD20 radioimmunotherapy is as efficacious as six to eight cycles of combination chemotherapy. A major question that persists is how effective these agents are in the setting of rituximab-refractory lymphoma. These products have been underutilised because of the complexity of treatment coordination and concerns regarding reimbursement.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available